염증성 장질환 시장 : 약제 클래스별, 적응 질환별, 투여 경로별, 유통 채널별, 지역별
Inflammatory Bowel Disease Market, By Drug Class, By Disease Indication, By Route of Administration, By Distribution Channel, By Geography
상품코드
:
1672834
리서치사
:
Coherent Market Insights
발행일
:
2025년 02월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 염증성 장질환 시장은 2025년에는 233억 4,000만 달러로 추정되고, 2032년에는 320억 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 CAGR 4.6%를 나타낼 것으로 예측됩니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
233억 4,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 CAGR(2025-2032년) |
4.60% |
금액 예측(2032년) |
320억 달러 |
그림. 염증성 장질환 지역별 시장 점유율(%)(2025년)
염증성 장질환(IBD)은 크론병과 궤양성 대장염이라는 두 가지 질환을 말하며, 소화관 내 만성 염증을 특징으로 합니다. IBD는 주로 소장과 대장을 침범하지만 때로는 소화기계의 다른 부위에 이르기도 합니다. IBD의 전형적인 증상은 환자마다 다르지만, 복통, 설사, 구토, 체중 감소, 피로를 반복하는 경우가 많습니다. 정확한 병인은 아직 알려지지 않았지만, IBD는 유전적으로 감수성이 높은 환자에서 환경적 유인에 대한 면역 반응이 부적절하게 제어됨으로써 발병하는 것으로 생각되고 있습니다. 현재 이용 가능한 치료법은 면역계의 다양한 구성요소를 표적으로 함으로써 관해를 유도 및 유지하는 것을 목적으로 하고 있습니다. 이러한 치료법은 치유를 초래하지 않기 때문에 IBD는 세계적으로 임상적이고 경제적으로 큰 부담이 되고 있습니다.
시장 역학
세계 염증성 장질환 시장의 개척은 라이프 스타일의 변화, 환경 리스크의 증대, 선진국의 수명 연장에 의한 크론병이나 궤양성 대장염의 유병률의 상승이 주요인입니다. 또한 신규 선택 요법과 개별화 요법의 개발에 초점을 맞춘 연구개발 증가, IBD의 조기 진단과 관리에 대한 의식이 높아지고, 주요 시장에서의 의료비 증가도 시장 성장의 원동력이 되고 있습니다. 그러나 엄격한 의약품 개발 규제 및 IBD 진단 도구 및 약물과 관련된 높은 비용이 시장 성장을 방해할 수 있습니다. 생물제제, 줄기세포, 유전자 치료 등의 연구개발이 진행되고 있는 것은 이해관계자에게 유리한 기회를 제공할 수 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 염증성 장질환 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모(10억 달러) 및 연간 평균 성장률(CAGR%)을 제공합니다.
- 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 상시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 세계의 염증성 장질환 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해관계자를 지원합니다.
- 이해관계자들은 세계의 염증성 장질환 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적 및 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map (COM)
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 영향 분석
- 시장 동향
- 규제 시나리오
- 인수 및 제휴 시나리오
- 자금 조달 및 투자
- PEST 분석
- Porter's Five Forces 분석
제4장 세계의 염증성 장질환 시장 : 코로나바이러스(COVID-19) 팬데믹의 영향
- 전체적인 영향
- 정부의 대처
- COVID-19에 의한 시장에 대한 영향
제5장 세계의 염증성 장질환 시장 : 약제 클래스별(2020-2032년)(10억 달러)
- 서문
- 코르티코스테로이드
- 아미노살리실산
- TNF 억제제
- 면역억제제
- 항생제
- 기타
제6장 세계의 염증성 장질환 시장 : 적응 질환별(2020-2032년)(10억 달러)
제7장 세계의 염증성 장질환 시장 : 투여 경로별(2020-2032년)(10억 달러)
제8장 세계의 염증성 장질환 시장 : 유통 채널별(2020-2032년)(10억 달러)
제9장 세계의 염증성 장질환 시장 : 지역별(2020-2032년)(10억 달러)
- 서문
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동
- 아프리카
제10장 경쟁 구도
- 기업 프로파일
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB SA
- Novartis AG
- Merck &Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics
제11장 분석가 추천
제12장 참고문헌 및 조사방법
AJY
영문 목차
Global Inflammatory Bowel Disease Market is estimated to be valued at USD 23.34 Bn in 2025 and is expected to reach USD 32.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 23.34 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
4.60% |
2032 Value Projection: |
USD 32.00 Bn |
Figure. Inflammatory Bowel Disease Market Share (%), By Region 2025
Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.
Market Dynamics:
Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.
Key Features of the Study:
- This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market
Detailed Segmentation-
- By Drug Class
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication
- Ulcerative Colitis
- Crohn's Disease
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB S.A.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Inflammatory Bowel Disease Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Aminosalicylates
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- TNF Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Immunosuppressant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Ulcerative Colitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Crohn's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Inflammatory Bowel Disease Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Biogen
- Amgen Inc.
- UCB S.A.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Gilead Sciences
- Bausch Health Companies Inc.
- Celltrion Healthcare Co., Ltd.
- CELGENE CORPORATION
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Sandoz
- Horizon Therapeutics
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
관련자료
